Oncology and Hematology

33-48 of 152

• 

  RestartResume

  Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies

  RestartResume

  Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies

  MinuteCE®

  Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies

  Joyce F. Liu, MD, MPH

  0.50 program credits

  • 

    

    Joyce F. Liu, MD, MPH

  0.50 program credits

• 

  RestartResume

  MOA: CDH6-Targeted Antibody-Drug Conjugates

  RestartResume

  MOA: CDH6-Targeted Antibody-Drug Conjugates

  MinuteCE®

  MOA: CDH6-Targeted Antibody-Drug Conjugates

  Kathleen Moore, MD, MS

  0.50 program credits

  • 

    

    Kathleen Moore, MD, MS

  0.50 program credits

• 

  MinuteCE®

  Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  

  James M. Cleary, MD, PhD

  0.50 credits 4 episodes

  • 

    

    James M. Cleary, MD, PhD

  0.50 credits 4 episodes

• 

  MinuteCE®

  Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  

  Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD

  0.50 credits 6 episodes

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Lauren A. Byers, MD

  0.50 credits 6 episodes

• 

  RestartResume

  Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 

  RestartResume

  Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 

  MinuteCE®

  Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 

  Lauren A. Byers, MD

  0.50 program credits

  • 

    

    Lauren A. Byers, MD

  0.50 program credits

• 

  RestartResume

  Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 

  RestartResume

  Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 

  MinuteCE®

  Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 

  Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD

  0.50 program credits

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Lauren A. Byers, MD

  0.50 program credits

• 

  RestartResume

  Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

  RestartResume

  Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

  MinuteCE®

  Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

  Luis Paz-Ares, MD, PhD

  0.50 program credits

  • 

    

    Luis Paz-Ares, MD, PhD

  0.50 program credits

• 

  RestartResume

  Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025

  RestartResume

  Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025

  MinuteCE®

  Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025

  Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD

  0.50 program credits

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Lauren A. Byers, MD

  0.50 program credits

• 

  RestartResume

  Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025

  RestartResume

  Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025

  MinuteCE®

  Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025

  Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD

  0.50 program credits

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Lauren A. Byers, MD

  0.50 program credits

• 

  RestartResume

  Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

  RestartResume

  Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

  MinuteCE®

  Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

  Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD

  0.50 program credits

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Lauren A. Byers, MD

  0.50 program credits

• 

  RestartResume

  Global Perspectives on Perioperative Immunotherapy in LA HNSCC

  RestartResume

  Global Perspectives on Perioperative Immunotherapy in LA HNSCC

  CME/CE

  Global Perspectives on Perioperative Immunotherapy in LA HNSCC

  Kevin J Harrington, PhD, FRCP, FRCR, FRSB; Christophe Le Tourneau, MD, PhD

  0.25 credits

  • 

    

    Kevin J Harrington, PhD, FRCP, FRCR, FRSB

  • 

    

    Christophe Le Tourneau, MD, PhD

  0.25 credits

• 

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  MinuteCE®

  Applications of Emerging Data in Resectable NSCLC

  Stephen Liu, MD; Joshua K. Sabari, MD

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  Hussein Tawbi, MD, PhD; Sapna Patel, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  Stephen Liu, MD; Joshua K. Sabari, MD

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  Sapna Patel, MD; John M. Kirkwood, MD

  1.00 program credit

  • 

    

    Sapna Patel, MD

  • 

    

    John M. Kirkwood, MD

  1.00 program credit

• 

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  MinuteCE®

  HER2-Driven Strategies in Metastatic NSCLC

  Stephen Liu, MD; Joshua K. Sabari, MD

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• Previous
• 1
• 2
• 3
• 4
• 5
• …
• 9
• 10
• Next